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The role of ascorbic acid in the treatment of asthma remains undefined. 
Ascorbic acid has previously been associated with partial protection 
against a number of asthmatic reactions. Since this agent is also known 
to modify prostaglandin synthesis a study was designed to examine the 
possible role of prostaglandins in exercise induced bronchospasm (EIB). 
Twelve subjects were recruited on the basis of a history consistent with 
EIB and the demonstration of a 20% decrease from baseline in MEF40% (P) 
during a preliminary exercise trial. On four subsequent test days the 
subjects ingested either: (1) 750 mg ascorbic acid, (2) 50 mg indometha- 
cin, (3) 750 mg ascorbic acid plus 50 mg indomethacin, or (4) a placebo. 
These substances were given in a double-blind, randomized, crossover fa¬ 
shion. Exercise challenge with pulmonary function testing was performed 
on each drug day. For the group as a whole this study did not demon¬ 
strate the previously described attenuation of EIB by ascorbic acid. 
Neither indomethacin alone or in combination with ascorbic acid influ¬ 
enced the post-exercise bronchoconsriction seen in this group. Never¬ 
theless, three subjects did demonstrate a consistent attenuation of EIB 
following treatment with ascorbic acid. The three "ascorbic acid re¬ 
sponders" could be separated from the other subjects on the basis of a 
lower baseline FEV1 (expressed as percent of the predicted value). 
These and previous observations suggest that the effect of ascorbic acid 
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EXERCISE INDUCED BRONCHOSPASM 
Exercise induced bronchospasm is a phenomenon that was described as ear¬ 
ly as the first century A.D. when Aretaeus the Cappadocian noted the as¬ 
sociation between strenuous exercise and acute airway obstruction (Ad¬ 
ams, 1856). This association, like many such early observations in 
medicine, was to be redescribed hundreds of years later. In 1698 Sir 
John Floyer not only redescribed exercise induced bronchospasm (EIB), 
but also pointed out that tasks having the highest levels of ventilation 
seemed to provoke the most severe wheezing (Floyer, 1698). Neither 
Floyer nor other researchers in the next two hundred and fifty years ap¬ 
preciated the full significance of this observation. 
Henry Hyde Salter, yet another keen observer whose thoughts were not 
appreciated until recently, recognized in 1864 that EIB was exacerbated 
by exercising in a cold environment (Salter, 1864). 
In 1946 Herxheimer performed the first study that objectively meas¬ 
ured changes in lung function in response to exercise (Herxheimer, 
1946). Herxheimer measured the change in vital capacity of asthmatics 
after exercise and postulated that hyperventilation was the key factor 
in EIB. A great deal of research was sparked by Herxheimer's findings. 
However, confusion and controversy surrounded this work on EIB. 
The first point of contention arose from studies by Capel and Smart 




ies, demonstrated an increase in FEV1 and lung compliance and a de¬ 
crease in airway resistance in asthmatics after exercise. Jones et al 
believed that this apparent variability in response to exercise was due 
to differences in the duration and intensity of the exercise in these 
different studies. He showed that this was indeed the case, as asthmat¬ 
ic children exercising for less than two minutes had a slight increase 
in FEV1, while those exercising for between eight and ten minutes had a 
consistent decrease in FEV1 after exercise (Jones, 1962). 
This initial confusion illustrates the principal sources of contro¬ 
versy in EIB research which for many years arose from the variability of 
the exercise challenges (type of exercise, duration, and intensity) and 
pulmonary function tests used to study EIB. These exercise challenges 
have included swimming (Fitch, 1971), stairclimbing (McNeill, 1966), 
free running (Jones, 1966), treadmill running (Sly, 1970), and cycling 
on a cycloergometer (Pierson, 1970). Parameters used to measure the re¬ 
sponse to exercise include FVC and TLC (Anderson, 1972), FEV1 (Jones, 
1963), PEFR (Sly, 1970), maximal mid-expiratory flow rates (MMEFR) and 
airway resistance or conductance (Haynes, 1976), as well as flow rates 
at low lung volumes on MEFV and PEFV curves (Schachter, 1978a). Given 
the variability of the challenge from study to study, as well as differ¬ 
ences in the severity of the asthma of the subjects studied, it is easy 
to see how estimates of the prevalence of EIB in asthmatics have ranged 
from nineteen percent (Cropp, 1975) to as high as ninety percent (Kivil- 
oog, 1975). The difficulty of studying the mechanism of EIB under such 
conditions can also be appreciated. 
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The issue of which parameters are the most sensitive and most accu¬ 
rate has been addressed by Bouhuys. Bouhuys observed that the more tra¬ 
ditional PFTs (such as FEV1 and PEFR) are not very sensitive to small 
changes in airway caliber and, moreover, are affected by the effort made 
by the subject performing the maneuver. These concepts are supported by 
a study by Pride which shows that subjects are able to attain an ade¬ 
quate PEFR even with significant obstruction if their vital capacity is 
adequate and ample effort is made (Pride, 1971). Other workers have 
also demonstrated that a deep inspiration, such as that made in generat¬ 
ing a MEFV curve, could by itself lead to transient bronchoconstriction 
(Lloyd, 1963 and Nadel, 1961). Bouhuys was able to show that this dif¬ 
ficulty could be avoided by using flow rates on PEFV curves, since the 
maneuver is made from only a partial inspiration (Bouhuys, 1969). Thus, 
Bouhuys advocated the measurement of instantaneous flow rates at lower 
lung volumes: MEF40% and MEF40%(P) (Bouhuys, 1976). Using such measure¬ 
ments in 1978 Schachter et al were able to demonstrate that in mild 
asthmatics the MEF40%(P) was the most sensitive parameter in detecting 
EIB (Schachter, 1978a). In Schachter's study, using a ten percent de¬ 
crease in a parameter as a significant response, MEF40%(P) identified 
EIB in sixteen of nineteen asthmatics, while none of the seven nonasth¬ 
matic controls were shown to have EIB. Only seven of the nineteen asth¬ 
matics would have been identified as having EIB if a ten percent drop in 
FEV1 had been used as the defining parameter. Thus, parameters using 




The other type of pulmonary function testing that has been used ex¬ 
tensively in measuring bronchoconstriction is volume displacement 
body plethysmography and the determination of airway resistance or spe¬ 
cific airway conductance (Bouhuys, 1969, Bouhuys, 1970, and Haynes 
1976). One problem with such measurements is that they are believed to 
be an indication of constriction of larger airways, while asthma (espe¬ 
cially mild bronchosapasm) may be a disorder of the smaller, more pe¬ 
ripheral airways. As obstruction becomes more severe in asthma, how¬ 
ever, larger airways are more likely to become involved. 
Despite the variability in the earlier studies following Herxheim- 
er's work, the early studies described a rather consistent course for 
EIB (Jones, 1962, McNeill, 1966, Godfrey, 1975, and Anderson, 1975). 
McFadden and Ingram describe EIB stating: 
The pattern of response to exercise is characteristic. Moder¬ 
ate bronchodilation occurs during the early part of exercise 
and gives way to bronchoconstriction after work ceases. The 
airway obstruction is progressive, generally reaching its peak 
5-10 min after exercise has stopped. The obstruction then be¬ 
gins to abate. Spontaneous recovery is usual, tending to be 
complete within 30-90 min, depending upon the severity of 
bronchospasm (McFadden, 1983). 
Thus, by the early 1970's EIB was a better characterized phenomenon. In 
addition, the development of more sensitive ways to measure EIB and new 
pharmacological agents were inspiring further studies addressing the pa¬ 
thogenesis of EIB. 
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THE TRIGGER OF EIB: RESPIRATORY HEAT LOSS 
A major question that interested investigators was what feature of 
exercise specifically triggers EIB. Three major factors were suspected: 
(1) hypocapnia from the hyperventilation of exercise, (2) stimulation of 
airway mechanoreceptors by hyperventilation, and (3) lactic acid release 
from skeletal muscle during exercise. Each of these hypotheses had sup¬ 
porting evidence, but conclusive studies awaited the development of a 
partial rebreathing technique that allowed the study of the effects of 
hypocapnia, hyperpnea, and acidosis independently of one another (McFad- 
den, 1977a). 
Support for hypocapnia as a cause of bronchoconstriction was based 
on three lines of evidence. First, Hafez and Crompton demonstrated 
that asthmatics had a decrease in FEV1 after voluntary hyperventilation 
that did not occur in bronchitics or control subjects. This decrease in 
FEV1 did not occur, however, in the subjects when hyperventilation was 
induced while the subjects were breathing 5% carbon dioxide (Hafez, 
1968). Second, Ferguson found the arterial partial pressure of carbon 
dioxide to be lower after exercise in patients with EIB than in healthy 
controls or even in patients with diffuse lung disease. As in the first 
study cited above, Ferguson's asthmatics had a post-exercise decrease in 
FEV1 that was blocked by the addition of carbon dioxide (3% in this 




that the administration of 6-8% carbon dioxide could prevent bronchos- 
pasm induced by running (Fisher, 1970). Of note, this EIB was not pre¬ 
vented by inhalation of atropine sulfate. 
Several other researchers, however, were obtaining results quite 
different from those claiming that hypocapnia was the trigger for EIB. 
Chan-Yeung demonstrated a correlation between the degree of hyperventi¬ 
lation and the post-exercise decline in FEV1, but found a greater de¬ 
cline in FEV1 when subjects inspired 5.6% carbon dioxide during exercise 
(Chan-Yeung, 1971). Stanescu and Teculescu reported the case of a pa¬ 
tient with EIB whose attacks were not prevented by inhaling as much as 
6.5% carbon dioxide (Stanescu, 1970). These workers, as well as other 
groups (Simonsson, 1972a, Bar-Or, 1977, and Sheppard, 1982), found some 
patients who experienced less bronchoconstriction from exercise, cold 
air, or hyperventilation when pre-treated with atropine. These authors 
postulated that EIB resulted from hyperventilation stimulating airway 
receptors acting via a vagal reflex. 
The use of a partial rebreathing technique by McFadden's group led 
to the conclusion that hypocapnia from hyperventilation was not the 
cause of EIB. This technique involved having subjects physically at 
rest breathing to simulate the minute ventilations reached in exercise, 
while varying the end-tidal carbon dioxide tensions. The bronchospasm 
produced by hypocapnia or hyperventilation, even with higher end-tidal 
carbon dioxide levels, were quite small in comparison to that produced 
by actual exercise (McFadden, 1977a). Hypocapnia did not adequately ac¬ 
count for the initiation of EIB. 
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Another factor proposed by other researchers as the inciting stimu¬ 
lus in EIB was the release of lactic acid resulting from the anaerobic 
metabolism of exercising muscles. Several studies (Seaton, 1969, Fish¬ 
er, 1970, and Vassalo, 1972) documented either a metabolic acidosis, in¬ 
creased lactate, or both in subjects with EIB. However, Silverman found 
that patients exercising on a treadmill had more severe EIB than those 
exercising on a bicycle, despite the subjects having higher arterial 
blood lactate levels during bicycling. Furthermore, the arterial blood 
pH was similar in the two forms of exercise (Silverman, 1972a). Strauss 
performed a study that convincingly eliminated acidosis as the stimulus 
for bronchoconstriction in exercise. The first part of this study in¬ 
volved measuring blood pH during exercise. The exercise challenge was 
then repeated while infusing enough sodium bicarbonate into each subject 
to prevent acidemia. All of the subjects experienced EIB of the same 
severity on both the control and bicarbonate days. The second part of 
this study involved the determination of the lowest amount of exercise 
and lactate level needed to precipitate EIB in each subject. This 
"threshold" dose of lactate was then infused into each subject at rest. 
None of the subjects developed bronchoconstriction with this lactic ac¬ 
idemia (Strauss, 1977a). This effectively ruled out a role for lactic 
acidemia as the trigger for EIB. 
The key to the initiation of EIB was elucidated by Deal and McFad- 
den's group once they returned to examine the very phenomenon observed 
by Salter in 1864: the effect of temperature on EIB. In their initial 
study on the effects of temperature they found that cold air had a rath¬ 
er small, but statistically significant, bronchoconstrictive effect on 
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resting asthmatic subjects. However, inspiring cold air during exercise 
caused a markedly enhanced bronchospastic response. Specific conduc¬ 
tance decreasd 85% and FEV1 decreased 100% more than when subjects exer¬ 
cised while breathing ambient air (Strauss, 1977b). Further studies by 
this group and others confirmed that the severity of EIB was determined 
not only by the temperature, but also by the humidity of the inspired 
air (Bar-Or, 1977, Chen, 1977, Strauss, 1978, Deal, 1979a, and Deal, 
1979b). Cooling and drying the inspired air caused increased bronchos- 
pasm, while heating and humidifying inspired air decreases the response 
to exercise. McFadden summarizes how this occurs in the airways as fol¬ 
lows : 
With exercise, as ventilation increases to meet metabolic de¬ 
mands, a large volume of air at ambient conditions is brought 
into the thorax where it must be heated to 37 degrees Centi¬ 
grade and fully saturated with water vapor before it reaches 
the alveoli. This requires evaporation of water and the 
transfer of heat from the mucosal surfaces of the airways. 
The colder the air, the drier it is, and so more heat and wa¬ 
ter are transferred, and so the more mucosal temperature 
drops. The degree of obstruction that develops is directly 
related to the total amount of heat transferred and so to the 
degree of cooling that develops.... (McFadden, 1981) 
This relationship can be quantified and it has been shown that respira¬ 
tory heat loss varies directly with the level of ventilation and in¬ 
versely with the temperature and humidity of the inspired air (Deal, 
1979a and Deal, 1979b). This respiratory heat loss, in turn, correlates 




BEYOND THE TRIGGER: THE AUTONOMIC NERVOUS SYSTEM 
While the theory of respiratory heat loss seems to have adequately 
explained the initiation of EIB, much controversy remains as to the 
mechanism by which airway cooling leads to bronchoconstriction. 
There are two areas of speculation on the effects of cooling of the 
airway that are worth mentioning briefly. Some preliminary in vitro an¬ 
imal studies "have shown that cooling of airway smooth muscle can cause 
constriction, as well as diminished responsiveness to isoproterenol." 
(McFadden, 1981) McFadden notes, however, that while there is no data 
for or against this in humans, the time course seen in the in vitro mod¬ 
el is wrong for a direct constrictor effect to be the sole explanation 
for EIB. He points out that as soon as exercise ends, the airways begin 
to rewarm and return to their baseline temperature within five minutes, 
while bronchospasm gets progressively worse over this same time period. 
Therefore, something else must be sustaining the obstruction. 
Another interesting speculation that is based on animal studies is 
the possibility of an interconversion of alpha and beta adrenergic re¬ 
ceptors. The idea here is that cooling of tissues leads to a conversion 
of beta receptors to alpha receptors, so that stimulation of smooth mus¬ 
cle with circulating catecholamines would produce contraction rather 
than relaxation (Haynes, 1976, Kunos, 1980, and McFadden, 1982). As 




this phenomenon in humans and there is still the problem with accounting 
for the time course of the obstruction in EIB. Furthermore, the evi¬ 
dence for the interconversion theory comes from submammalian species and 
is controversial in its own right (Benfey, 1980). 
The role of the autonomic nervous system in EIB remains controver¬ 
sial. The adrenergic system has been implicated in asthma in many dif¬ 
ferent ways. Beta adrenergic stimulation has been shown to produce 
bronchodilatation (believed to be through activation of adenylate cyc¬ 
lase and increasing cAMP levels in smooth muscle cells) and to suppress 
IgE dependent release of mediators from lung tissue (Orange, 1971 and 
Webb-Johnson, 1977). Much evidence has accumulated showing asthmatics 
to be hyporesponsive to beta adrenergic stimulation (Reed, 1974 and 
Szentivanyi, 1976). Some workers have found an exaggerated rise in cir¬ 
culating catecholamines in asthmatics during exercise, which they postu¬ 
late is an attempt to overcome receptor hyposensitivity (Griffiths, 1972 
and Beil, 1977). Others have found no differences in catecholamine lev¬ 
els between asthmatics and healthy controls (Anderson, 1976 and Chrys- 
santhopoulos, 1978). One group has even reported a decreased catechola¬ 
mine response following exercise in asthmatics using a newer assay 
(Barnes, 1981b). 
Studies using beta blockers in EIB have raised the possibility of a 
role for alpha adrenergic involvement in EIB. A role for alpha adrener¬ 
gic hyperresponsiveness has been suggested by four lines of evidence: 
(1) increased EIB after beta blockade (Grieco, 1971 and Jones 1972), (2) 
bronchoconstriction on administration of catecholamines after beta 
blockade (Simonsson, 1972b, Prime, 1972, and Patel, 1973), (3) reduced 
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EIB in some patients after alpha blockade (Bianco, 1974, Patel, 1976, 
and Biel, 1978), and (4) greater response to alpha stimulation in asth¬ 
matics as measured by vascular and pupillary response (Henderson, 1979). 
However, there are other studies showing that asthmatics may respond to 
alpha blockade with bronchoconstriction rather than dilatation (Spector, 
1979 and Shiner, 1983). Thus, no consistent picture emerges for an 
adrenergic role. 
The possible role of the parasympathetic branch of the nervous sys¬ 
tem in EIB was already mentioned since the mechanoreceptor theory for 
EIB was postulated to involve a vagal reflex. 
While heat flux, and not mechanical stimulation, is now the accepted 
mechanism for the initiation of EIB, it has been suggested that a vagal 
reflex may still mediate EIB if there are temperature sensitive neural 
receptors in the airways (Enright, 1979 and McNally, 1979). Studies 
supporting this theory have found decreased EIB after the application of 
a topical anesthetic to the posterior pharynx and upper airways. The 
authors postulate that the topical anesthesia interrupts the vagal re¬ 
flex. These studies, however, did not adequately control for ventila¬ 
tion rate or inspired air conditions. When subsequent studies were done 
with appropriately controlled conditions, the initial results were not 
duplicated (Fanta, 1980 and Griffin, 1982). 
Further confusion on the role of vagal reflexes has arisen because 
some investigators have shown that atropine (or other anticholinergic 
agents) can attenuate bronchospasm produced by exercise, hyperventila¬ 
tion, or cold air breathing. This was found in some asthmatics, but not 
in others (Stanescu, 1970, Crompton, 1968, McNeill, 1966, Simonsson, 
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1972a, Breslin, 1980b, Deal, 1978, McFadden, 1977b, Rasmussen, 1979, and 
Thomson, 1978). Different inspired air conditions have also been found 
to have an influence on the effectiveness of anticholinergics (Deal, 
1978 and Breslin, 1980b). Alternative explanations for these variable 
results have been: (1) the mechanism for the obstruction has more than 
one determinant (Thomson, 1978, Rasmussen, 1978, and McFadden, 1980), 
(2) anticholinergics influence respiratory heat loss themselves (Bres¬ 
lin, 1980b), and (3) the possibility that inadequate doses of atropine 
may have been used in some studies (Sheppard, 1982). 
Despite the above arguments against cholinergic mediation of EIB, 
cholinergic agonists are known to enhance mediator release (Kaliner, 
1972 and Kaliner, 1977) and there is a positive correlation between 
asthmatic subjects' sensitivity to methacholine challenge and the sever¬ 
ity of their EIB (Kiviloog, 1973). Thus, the autonomic nervous system 
may well play a role in EIB, though how important a role is yet to be 
determined. Current consensus suggests that the autonomic nervous sys¬ 




BEYOND THE TRIGGER: MEDIATORS 
The other major area of research concerning the mechanism of airway 
obstruction in EIB has been the role of chemical mediators. This is a 
field that has seen a tremendous amount of activity in the past fifteen 
years. Many mediators have only recently been identified in their pure 
biochemical form, while still others have yet to be isolated and com¬ 
pletely characterized. Much of the work on mediators in EIB has been 
suggested by the findings involving mediators in allergic asthma. 
Before reviewing the literature on specific mediators, it will be 
helpful to examine the evidence for and against mediators in EIB in gen¬ 
eral. In a study of considerable interest in 1977, Soter and Austen 
demonstrated mediator release from sensitized mast cells in the cooled 
skin of patients with cold urticaria (Soter, 1977). By analogy some au¬ 
thors have postulated that a similar phenomenon occurs with cooling of 
the airways in EIB. 
The drug disodium cromoglycate (DSCG) has been shown to inhibit 
bronchoconstriction due to exercise and isocapnic hyperventilation, but 
only if given before these challenges (Silverman, 1972b, Haynes, 1976, 
and Breslin, 1980a). This drug does not usually affect baseline airway 
tone. As the main mode of action of DSCG is believed to be the stabili¬ 
zation of mast cell membranes, this work would explain DSCG preventing 




Other drugs that also prevent mast cell degranulation , such as diethyl- 
carbamazine pamoate (Sly, 1974a), beta adrenergic agonists (Godfrey, 
1976), and calcium channel blockers (Cerrina, 1981 and Patel, 1981), 
have also prevented EIB in some trials. 
The last line of indirect evidence supporting a role for mediator 
release in EIB comes from the existence of a "refractory period" in EIB. 
If exercise challenges are repeated at short intervals, the bronchospas- 
tic response decreases (McNeill, 1966, James, 1976, and Edmunds, 1978). 
This has been interpreted by some as evidence for the depletion of a 
stored mediator that must be regenerated over a period of time. 
Nevertheless, some work has cast doubt on the role of mediators in 
EIB. DSCG has been shown to decrease the bronchospastic response to 
cold air in normal subjects and to sulfur dioxide (an irritant gas) in 
both asthmatics and normal controls (Fanta, 1981, Harries, 1981, and 
Sheppard, 1981). Since neither of these situations are believed to in¬ 
volve mediator release, DSCG may well work by other mechanisms. Thus, 
the role of DSCG in EIB may involve an effect other than decreasing me¬ 
diator release. Just the fact that normal individuals, who do not have 
sensitized mast cells, can be made to develop obstruction with exercise 
and other similar stimuli is cited as evidence against mediator involve¬ 
ment (at least mediators from mast cells) (McFadden, 1983). 
This controversy over mediators extends into the literature on spe¬ 
cific mediators. Histamine was examined first because of the known re¬ 
lease of histamine during mast cell degranulation in allergen induced 
asthma (Valentine, 1976). While one earlier paper showed no increase in 
histamine turnover during exercise in subjects with EIB (Granerus, 
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1971), other workers have demonstrated increases in either arterial or 
venous plasma histamine levels that are correlated with decreased PFTs 
in EIB (Ferris, 1978, Barnes, 1981a, Anderson, 1981, and Lee, 1982a). 
However, Deal and McFadden's group found no increase in arterial hista¬ 
mine levels following challenge by isocapnic hyperventilation with cold 
air (a stimulus equivalent to exercise) (Deal, 1980). 
Interestingly, in the same above mentioned study. Deal and McFadden 
failed to find an increase in neutrophil chemotactic activity (NCA) when 
subjects performed isocapnic hyperventilation with cold air. They took 
this finding to support their conclusion that mast cell derived media¬ 
tors are not involved in EIB. NCA is a heat-stable, high molecular 
weight factor that was first described in antigen induced asthma by At¬ 
kins (Atkins, 1977). It is the same mediator that was found to be asso¬ 
ciated with the phenomenon of cold induced urticaria mentioned earlier 
(Wasserman, 1977). NCA has since been shown to be present in the serum 
of asthmatic subjects after exercise on a treadmill and has even been 
partially purified (Lee, 1982b). The time course for the release of NCA 
is quite similar to that of histamine release. Lee repeated Deal's 
study, but used a treadmill challenge looking for NCA release. This 
time the exercise was performed once while inspiring warm, humid air and 
on a second occasion with subjects breathing cold, dry air (Lee, 1983). 
This study showed that EIB and NCA both appeared together during the 
cold exercise challenge, while neither were produced during the hyper¬ 
ventilation with warm air. These results were interpreted as demon¬ 
strating that respiratory heat exchange and exercise (by some unknown 
additional mechanism) together cause mast cell mediator release. Lee 
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further postulated that isocapnic hyperventilation might cause mediator 
release, but at levels that are only detectable with the addition of ex¬ 
ercise. Lee reviewed some of the literature already discussed above on 
vagal reflexes and suggested that different sites and mechanisms of air¬ 
way obstruction may exist in different subjects. One additional study 
that supports this multiplicity of mechanisms involved exercising pa¬ 
tients repeatedly at short intervals until they no longer responded with 
EIB. These subjects were then challenged with an allergen known to pro¬ 
duce bronchospasm in the subjects. Six of the twelve subjects in this 
study remained responsive to the allergen while the other six were not 
(Weiler-Ravell, 1981). One would expect all of the subjects to be una¬ 
ble to respond to the allergen if the exercise had depleted the media¬ 
tors necessary to produce bronchospasm. Thus, the subjects in Weiler- 
Ravell' s study may represent two subgroups of of people with EIB: those 
with mediator-dependent EIB and those with EIB produced via another 
mechanism. 
Slow reacting substance of anaphylaxis (SRS-A) is another important 
mediator of allergen (Ig E) dependent bronchoconstriction that has been 
investigated extensively in recent years (Orange, 1969). In contrast to 
histamine and NCA, SRS-A is extractable from lung cells only after immu¬ 
nological challenge and, thus, is not a preformed, stored mediator 
(Brocklehurst, 1960). While the need for an immunological stimulus for 
release of SRS-A seems to speak against its involvement in EIB, there 
are a few reasons for briefly mentioning SRS-A here. First, many modu¬ 
lators of EIB were first discovered in work on allergen induced asthma 
and there simply has not been much work to date on the role of SRS-A in 
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EIB. Second, there are two studies that suggest that SRS-A is involved 
in EIB. The drug diethylcarbamazine citrate, which has been shown to 
inhibit SRS-A release in rats (Orange, 1968), prevented EIB in fifteen 
of twenty asthmatic subjects when given before exercise challenge (Sly, 
1974b). Lastly, SRS-A has been characterized as consisting of three 
distinct leukotrienes (LTs): LTC4, LTD4, and LTE4. These leukotrienes 
are derivatives of arachidonic acid and are closely related to and in¬ 
teract with prostaglandins (Murphy, 1979, Morris, 1980, Lewis, 1980, Co¬ 
rey, 1980, and Samuelsson, 1982). 
Leukotrienes are released by human lung fragments when challenged 
with allergen (Orange, 1973 and Austen, 1974) and have been shown to be 
very potent spasmogens on isolated human bronchi (Dahlen, 1980). LTC 
and LTD are also potent constrictors of human airways in vivo (Holroyde, 
1981 and Weiss, 1982). How leukotrienes produce these effects is the 
subject of much current research, with one area of interest being the 
interaction of leukotrienes and prostaglandins. After all, both classes 
of compounds are derived from arachidonic acid with the enzymes lipox¬ 
ygenase and cyclooxygenase being the first step in the production path¬ 
way for leukotrienes and prostaglandins, respectively. In vitro animal 
studies have suggested that in some situations leukotrienes may act via 
the production of thromboxane, a product of the cyclooxygenase pathway 
(Piper, 1981, Schianterellli, 1981, and Folco, 1981). Interestingly, 
studies using inhibitors of various steps in arachidonic acid metabolism 
seem to indicate that LTD4 (at least) has both a thromboxane mediated 
and a direct bronchoconstrictive effect (Muccitelli, 1983 and Weichman, 
1984). Further elucidation of the actions and mechanisms of leuko- 







Prostaglandins are the products of the cyclooxygenase pathway of ar- 
achidonic acid metabolism. Earlier work on prostaglandins in asthma was 
initially centered on prostaglandins E2 and F2'< (PGE2 and PGF2<*.). Both 
are formed in high concentrations in the lung relative to the rest of 
the body (Karim, 1967), with lung parenchyma having much more PGF2« than 
PGE2, while isolated bronchi have been found to have a predominance of 
PGE2 (Shaw, 1975). Several lines of evidence exist to suggest the in¬ 
volvement of PGE2 and PGF2 in the regulation of airway tone. PGE2 is a 
bronchodilator in vitro (Sweatman, 1968 and Gardiner, 1975) and in vivo 
(Smith, 1973 and Smith, 1975a), while PGF2°< is a bronchoconstrictor both 
in vitro (Sweatman, 1968 and Gardiner, 1975) and in vivo (Smith, 1975a, 
Mathe, 1973, Mathe, 1975, and Newball, 1977). Like many other potential 
mediators, PGF2*< is a far more potent bronchoconstrictor in asthmatics 
than in normal subjects (Newball, 1980). The effects of these prosta¬ 
glandins are not altered by antihistamines or anticholinergics, suggest¬ 
ing that the effects are independent of other mediators and the autonom¬ 
ic nervous system (Sweatman, 1968 and Shaw, 1975). Some studies suggest 
that PGE2 and PGF2®< may act either through changing cyclic nucleotide 
metabolism (Shaw, 1975) or via an effect on calcium and smooth muscle 
contraction (Carsten, 1972, Higgins, 1972, and Shaw, 1975). Other stud¬ 




either the release of or the sensitivity to histamine (Tauber, 1973 and 
Walters, 1983). 
As with leukotrienes, prostaglandins have been implicated in aller¬ 
gic asthma by studies that have shown the release of PGF2°c from human 
lung fragments that had been passively sensitized and then subjected to 
antigen challenge (Piper, 1973). The principal metabolite of PGF2* has 
also been shown to be elevated in the plasma of subjects after an anti¬ 
gen inhalation challenge (Green, 1974). 
Prostaglandin D2 (PGD2) and thromboxane A2 (TXA2) are two other cy¬ 
clooxygenase products that have been investigated recently in a fashion 
similar to previous work on PGE2 and PGF2** . These substances are also 
released by sensitized lung fragments in vitro when challenged with an¬ 
tigen (Schulman, 1980a and Schulman, 1980b). In fact, PGD2 and TXA2 are 
more potent bronchoconstrictors than PGF2°<. in vitro (Hamberg, 1975 and 
Svensson, 1977), and PGD2 is more potent than PGF2«< when inhaled by hu¬ 
mans (Hardy, 1984). Furthermore, PGD2 is released in larger quantities 
than PGF2°< in allergen challenged lung tissue as well (Schulman, 1981, 
Lewis, 1982, and Peters, 1983). 
From the literature cited above it is clear that prostaglandins are 
involved at least in allergic asthma, though there are a lot of ques¬ 
tions remaining to be answered. One interesting dilemna concerns non¬ 
steroidal anti-inflammatory drugs (NSAIDs) such as indomethacin. These 
drugs are inhibitors of cyclooxygenase and, thus, they block prostaglan¬ 
din synthesis (Vane, 1971 and Flower, 1972). If the generation of bron- 
choconstrictive prostaglandins is responsible for airway obstruction in 
EIB, then one might expect NSAIDs to be bronchodilators, or at least 
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prevent bronchospasm. Indeed, Szczeklik has reported a small group of 
asthmatic subjects who do have bronchodilatation in response to aspirin, 
another NSAID (Szczeklik, 1983). However, it is also well known that 
there are subjects who develop asthma attacks in response to NSAIDs 
(Szczeklik, 1975). Furthermore, there are studies documenting that 
NSAIDs have no effect (either increasing or decreasing) on the broncho- 
constriction elicited by allergen (Smith, 1975b and Fish, 1981), exer¬ 
cise (Rudolph, 1975, Smith, 1975c, and Schachter, 1978b), or methacho- 
line (Ogilvy, 1981) in asthmatic or normal subjects. 
The literature on the role of prostaglandins in EIB is not very ex¬ 
tensive, due in part to the difficulty of measuring prostaglandins in 
vivo and perhaps also to early negative studies. Allegra found PGE 
plasma levels to be significantly higher in asthmatics at rest than in 
normal controls (Allegra, 1976). He postulated that this might be a 
compensatory mechanism to raise cAMP in asthmatics who have beta adren¬ 
ergic hyposensitivity. (This is similar to the argument discussed ear¬ 
lier that was put forth by those who found baseline catecholamine levels 
elevated in asthmatics.) Allegra1s group, however, did not find a sig¬ 
nificant difference between pre- and post-exercise plasma levels of PGE 
and PGF2« in asthmatic subjects exercised on a treadmill (Field, 1976). 
Another group of workers actually found a significant decrease in the 
plasma level of the major metabolite of PGF2°< during EIB (Anderson, 
1976). This, of course, is contrary to what one would expect if EIB 
were caused by an increase in PGF2‘<. This group of workers concluded 
that PGF2°< does not play a significant role in EIB. The other possibil¬ 
ity suggested by Allegra1s group is that systemic sampling from the pe- 
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ripheral plasma is just not sensitive enough to measure what may be 
quite significant changes in local prostaglandin concentrations within 
the lung tissue (Field, 1976). It may be that even very sensitive pros¬ 
taglandin assays in the future will be unable to measure systemic chang¬ 
es if the entire process is localized and rapid. This issue is espe¬ 
cially important in light of the finding by Newball that intravenous 
PGF2<*, even in doses large enough to produce uterine contractions and 
watery diarrhea in some subjects, produced much less bronchoconstriction 
than smaller doses of inhaled PGF2<< (Newball, 1976). It should be noted 
that this difficulty is present to some extent where any attempt is made 
to measure any proposed chemical mediator in a clinical trial. 
As mentioned earlier, studies showing no effect of cyclooxygenase 
inhibitors on EIB speak against a primary role for prostaglandins in 
EIB. However, there is one study by Souza and Silverman that looked at 
the effects of a single oral dose (25 mg) of indomethacin on EIB. They 
found that five of the twelve subjects were at least partially protected 
against EIB by the indomethacin (Souza, 1981). It must be pointed out, 
however, that this study used PEFR as an indicator of EIB, while two of 
the three negative studies alluded to earlier used the more sensitive 
•indicators FEV1 and MEF40%(P) (Smith, 1975a and Schachter, 1978b). 
Two studies have shown that DSCG does not protect against bronchos- 
pasm induced by inhalation of PGF2 (Patel, 1975 and Newball, 1977). 
These researchers used this data to conclude that the bronchoconstric- 
tive action of PGF2*< is due to a direct effect on airway smooth muscle. 
These studies also present indirect evidence against the role of PGF2°c 
in EIB since DSCG does protect against EIB in many subjects, yet it does 




The possibility that ascorbic acid might be involved in asthma was 
first raised in the early nineteenth century by Reisseissen, who de¬ 
scribed symptoms of asthma in patients with severe scurvy (Reisseissen, 
1803). This observation suggests the following question: if ascorbic 
acid deficiency can produce asthma, can ascorbic acid prevent or amelio¬ 
rate asthma in non-scorbutic asthmatics? 
While this issue does not compare with the uproar surrounding the 
question of the effect of ascorbic acid on cancer or the common cold, 
there is controversy over the effect of ascorbic acid on asthma. The 
question of the protective effect of ascorbic acid in asthma has been 
raised in many different ways. One of the first therapeutic trials was 
performed by Hunt in 1938. He was unable to demonstrate any benefit 
from a daily oral dose of 100 mg of ascorbic acid, as measured by the 
number and severity of bronchospastic episodes in asthmatic subjects. 
Hunt also found no benefit from the intramuscular or intravenous injec¬ 
tion of ascorbic acid (500-800 mg doses) given during acute asthmatic 
episodes (Hunt, 1938). 
Another simple clinical trial was performed more recently in Nige¬ 
ria. 41 asthmatics, all of whom had increased numbers of attacks during 
the country's rainy season, were studied. These patients had exacerba¬ 




by the report of sore throat and dry cough). 22 of these subjects took 
one gram of ascorbic acid daily for 14 weeks, while the other 19 sub¬ 
jects took a placebo for the same length of time. During this trial the 
subjects receiving ascorbic acid had fewer asthmatic episodes and far 
less severe attacks than those in the placebo group. Interval measure¬ 
ments of plasma ascorbic acid levels confirmed a significantly greater 
level in the subjects assigned to the ascorbic acid group (Anah, 1980). 
While this study did not involve a crossover of treatment regimens, 
there was a marked increase in the number and severity of asthma attacks 
for the ascorbic acid subjects once the trial was terminated. Obvious¬ 
ly, there are many problems with this study, including reliance on 
self-reporting of attacks and their severity without any objective meas¬ 
urement of lung function, but the most important difficulty seems to be 
the selection of a group of patients whose attacks were precipitated by 
respiratory infections. This study claims to have demonstrated a bene¬ 
ficial effect of ascorbic acid in asthma, but may actually have been 
measuring a protective effect of ascorbic acid against respiratory in¬ 
fections . 
Other more rigorous studies have looked at the effects of ascorbic 
acid against bronchoconstriction produced by means other than respirato¬ 
ry infections. Bouhuys initially demonstrated an inhibition of hista¬ 
mine induced bronchoconstriction in healthy subjects following single 
oral doses of 500 mg of ascorbic acid (Zuskin, 1973). Workers in the 
same lab later were unable to document this protective effect in asth¬ 
matic subjects treated for three days with 500 mg ascorbic acid daily 
(Kreissman, 1977). A study by Cockroft et al also failed to show a pro- 
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tective effect of one gram doses of ascorbic acid against histamine in¬ 
duced bronchospasm in asthmatics (Cockroft, 1977). Similarly, studies 
of asthma induced by textile dust inhalation have demonstrated inhib¬ 
ition of bronchospasm by ascorbic acid (Valic, 1973 and Zuskin, 1977), 
while other investigators using ragweed as the antigen found no benefit 
from the use of ascorbic acid (Kordansky, 1977 and Kordansky, 1979). 
Single oral doses of one gram of ascorbic acid decreased methacholine 
induced bronchospasm in both healthy subjects (Ogilvy, 1981) and asth¬ 
matics (Mohsenin, 1983). One study of ascorbic acid in EIB utilized one 
gram of ascorbic acid given intravenously 2.5 hours prior to exercise 
and then measured the response to exercise by PEFR and MMEFR. In this 
investigation ten subjects were studied: two had a decrease in EIB, two 
had an increase in EIB, and six subjects had no change in the severity 
of EIB after infusion of ascorbic acid (Anderson, 1983). It is impor¬ 
tant to note, however, that one of the parameters used to determine the 
pulmonary response to exercise was the PEFR. As mentioned earler, this 
measurement is effort dependent and may not be reliable. Since Ander¬ 
son's paper did not show specific data, it is possible that reliance on 
this parameter may have led to spurious conclusions. 
Finally, one other study on ascorbic acid and EIB, performed by 
Schachter and Schlesinger, did demonstrate the beneficial effects of as¬ 
corbic acid (Schlesinger, 1980 and Schachter, 1982). Their study in¬ 
volved pre-treatment with 500 mg of ascorbic acid or a placebo ninety 
minutes prior to exercise challenge. The subjects in the study all had 
a history of mild asthma and documented EIB (at least a 20% drop in 
MEF40% or MEF40%(P) on an exercise challenge on a prior screening day). 
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PFTs were measured at the following times: before exercise, immediately 
after exercise, five minutes after exercise, and after the administra¬ 
tion of a bronchodilator. FVC and FEV1 were the parameters that most 
consistently demonstrated the protective effect of ascorbic acid, al¬ 
though MEF40%(P) was the most sensitive indicator of bronchoconsfric¬ 
tion. 
In vivo animal studies and in vitro experiments have demonstrated 
the anti-bronchospastic actions of ascorbic acid and have been used to 
suggest the mechanism, or mechanisms, by which this protective effect is 
attained. Early work centered on the interaction of ascorbic acid and 
histamine, since some studies showed that ascorbic acid protects against 
anaphylaxis induced by antigen or histamine in various animals (Guirgis, 
1965, and Dawson, 1965, 1966, and 1967). Chatterjee et al found that 
guinea pigs on an ascorbic acid free diet developed markedly elevated 
histamine levels in plasma and other tissues (Chatterjee, 1975). Fur¬ 
ther work by this group suggested that ascorbic acid had this effect by 
influencing the metabolism of histamine (Subramanian, 1978). Some other 
possible mechanisms for the effect of ascorbic acid that have not been 
well evaluated are reviewed by Schlesinger (Schlesinger, 1980). These 
include an effect on cyclic nucleotide metabolism, smooth muscle cell 
calcium flux, and a direct effect on airway smooth muscle related to the 
action of ascorbic acid as an antioxidant. 
The area that has produced exciting research in recent years has 
been the studies of the interaction between ascorbic acid and prosta¬ 
glandins. Puglisi et al have found an increased production of PGE2 (the 
brochodilating PG) in guinea pig tracheal tissue treated with ascorbic 
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acid (Puglisi, 1977). In a complementary study, this group also demon¬ 
strated that more PGF2°<. (the bronchoconstricting PG) than PGE2 was pro¬ 
duced by tracheal tissue from scorbutic guinea pigs (Puglisi, 1976). 
They also discovered that in vivo treatment of guinea pigs with ascorbic 
acid antagonized the bronchoconstriction induced by intravenous PGF2°* 
(Puglisi, 1976). This work led to the attractive hypothesis that ascor¬ 
bic acid alters PG metabolism in favor of PGE2 production over PGF2<* re¬ 
sulting in a net bronchodilating effect. Two clinical studies showing 
the protection by ascorbic acid against methacholine induced bronchos- 
pasm support this hypothesis, since the administration of the PG synthe¬ 
sis inhibitor indomethacin blocked the beneficial action of ascorbic 
acid (Ogilvy, 1981 and Mohsenin, 1983). In these studies indomethacin 
had no effect on methacholine induced bronchospasm when given by itself 
and neither ascorbic acid nor indomethacin had a significant effect on 
resting airway tone. Despite the lack of effect on resting tone, ascor¬ 
bic acid protected against methacholine, while ascorbic acid and indome¬ 
thacin given together failed to attenuate the bronchospasm induced by 
methacholine. Thus, these investigators postulated that ascorbic acid 
protects against EIB by altering active prostaglandin metabolism so that 
PGE2 production is predominant over PGF2°c. 
Exactly how ascorbic acid alters arachidonic acid and prostaglandin 
metabolism is not known, but has been the subject of additional in vitro 
studies. It was mentioned earlier that ascorbic acid is an antioxidant 
and, thus, alters the redox potential of any system to which it is add¬ 
ed. Since it had been shown that reduced glutathione increases the pro¬ 
duction of PGE2 (Lands, 1971), some authors have suggested that ascorbic 

28 
acid might increase PGE2 by maintaining glutathione in the reduced state 
(Lands, 1971 and Puglisi, 1977). However, two studies have shown no 
correlation between ascorbic acid and glutathione levels in lung tissue 
(Leung, 1981 and Rothberg, 1983). One of these studies, by Rothberg and 
Hitchcock, did demonstrate that lung microsomes from scorbutic animals 
did produce more PGF2<< than microsomes from control animals when the ex¬ 
periment was run at low arachidonic acid concentrations (Rothberg, 
1983). They suggest that, as ascorbic acid does protect against some 
oxidase enzymes (Danford, 1980), ascorbic acid may actually increase the 
conversion of PGF2«c to PGE2. 
The aim of the present study was to first confirm the existence of a 
protective effect of ascorbic acid against EIB. Secondly, it was ex¬ 
pected that if the protective effect was due to an alteration in prosta¬ 
glandin metabolism, then the benefit of a dose of ascorbic acid would be 
blocked by simultaneous adminstration of indomethacin. Thus, we postu¬ 
lated that we would obtain results similar to those seen in the studies 





Asthmatic subjects were recruited for this study by advertising in 
the university community for persons with mild asthma. Clinic and hos¬ 
pitalized patients were not solicited because of their tendency to have 
more severe asthma. All subjects had a history of asthma as defined by 
the American Thoracic Society (Amer Thor Soc, 1962). None of the sub¬ 
jects required corticosteroid therapy at the time of the study. While 
subjects had asthma attacks at varying frequencies, no subject had re¬ 
quired hospitalization for an attack. All subjects gave written in¬ 
formed consent as approved by the Yale University Human Investigations 
Committee. 
Each subject completed a questionnaire detailing respiratory symp¬ 
toms, allergies, medications, medical illnesses, smoking history, and 
history of EIB. Subjects were instructed to take no asthma medications 
or prostaglandin synthesis inhibitors (aspirin, ibuprofen, etc.) for 
twenty-four hours prior to each test day. They were also instructed to 
refrain from ingestion of any food or beverage containing large amounts 
of methylxanthines (coffee, tea, cocoa, soft drinks, etc.) or ascorbic 
acid (citrus fruits, juices, etc.) for twenty-four hours prior to test¬ 
ing. In order to be enrolled in this study each patient had to demon¬ 
strate at least a 20% reduction from their baseline MEF40%(P) on a 




to exercise without any test drugs. A total of twelve subjects, eight 
male and four female, were entered into the study. 
Pulmonary function testing (PFTs) consisted of forced expiratory 
volumes and flow rates derived from partial and maximal expiratory flow 
volume curves (PEFV and MEFV curves). These curves were generated by 
the use of a pneumotachograph integrator system and were recorded on a 
Gould X-Y recorder. The PEFV curve was created by having the subjects 
inspire to approximately two-thirds of vital capacity and then exhale 
forcefully to residual volume. They would then immediately inspire to 
total lung capacity and exhale forcefully to residual volume once again, 
thus generating the MEFV curve. The parameters obtained from these 
curves were the following: 
1. forced vital capacity (FVC), 
2. forced expiratory volume in one second (FEV1), 
3. peak expiratory flow rate (PEFR), 
4. flow rate after expiration of 50% of the volume of a maximal in¬ 
spiration (Vmax50%), and 
5. flow rates at 60% of baseline vital capacity below total lung ca¬ 
pacity on both MEFV and PEFV curves (MEF40% and MEF40%(P)). 
Exercise testing was performed in an air-conditioned laboratory 
where the room temperature and humidity were relatively constant: temp¬ 
erature = 68 +/- 2° F (range = 62-74°) and humidity = 59 +/- 7% (range = 
50-71%). 
Subjects exercised on a cycloergometer (Monark). Subjects began pe¬ 
daling at a speed of 20 km/hr against a zero workload. At the end of 
each one minute interval the subjects' heart rate was measured with an 
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electrocardiograph (Hewlett-Packard) and minute ventilation was measured 
by directing exhaled air through a calibrated gas meter. Once these 
values were recorded the workload was increased by 150 kilopond-meters/ 
minute with subjects continuing to pedal at a rate of 20 km/hr. Sub¬ 
jects continued this constant rate against increasing workloads until 
either the heart rate exceeded 170 beats/minute or the subject was too 
fatigued to go on. 
While exercising the subjects inspired through a mouthpiece connected 
to an Otis-McKerrow valve. A length of tubing connected the intake por¬ 
tion of the valve and mouthpiece to a column filled with calcium sulfate 
granules (Drierite) with the other end of the column open to room air. 
The outflow from the mouthpiece was directed through more tubing to the 
calibrated gas flow meter. Subjects wore a nose clip so that they would 
only be breathing the dried air through the mouth, bypassing the warming 
and humidifying effects of the nasopharynx. This kind of experimental 
apparatus produces an average partial pressure of water vapor of 3 mm of 
Hg in the inspired air (Schachter, 1984). 
As mentioned above, subjects refrained from the use of asthma medi¬ 
cations and substances containing methylxanthines or ascorbic acid for 
twenty-four hours prior to each test day. Each subject was tested at 
approximately the same time of day (+/- 2 hrs.) on all trial days to 
avoid any diurnal variation. Whenever PFTs were measured, subjects per¬ 
formed the PEFV and MEFV maneuvers three times, with one minute inter¬ 
vals between each pair of curves. Thus, the values for any PFT parame¬ 
ter at a given time point were actually taken to be the average of the 
values from the three sets of curves. 
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On the initial screening day a baseline set of PFTs was obtained. 
Subjects then exercised according to the protocol described above. 
Three pairs of PEFV and MEFV curves were then obtained at the following 
times after completion of exercise: 
1. one minute, 
2. five minutes, 
3. fifteen minutes, 
4. thirty minutes, and 
5. sixty minutes. 
After the sixty minute PFTs each subject received two metered doses 
(0.65 mg each) of metaproterenol sulfate (Alupent) inhaler. Ten minutes 
after the administration of this bronchodilator a final set of PFTs was 
measured (post-alupent curves). A subject had to experience at least a 
20% reduction in MEF40%(P) from pre-exercise values at some point after 
exercise to have sufficient EIB to go on to the rest of the study. 
The remainder of the study consisted of four trial days. On each 
day a pre-drug baseline set of PFTs was obtained. Subjects then re¬ 
ceived two capsules that contained one of the following combinations: 
1. two placebos (lactose), 
2. one placebo plus 750 mg of ascorbic acid, 
3. one placebo plus 50 mg of indomethacin, or 
4. 750 mg of ascorbic acid plus 50 mg of indomethacin. 
These were given in a double-blind, randomized, crossover fashion such 
that each subject received all four combinations, just in different or¬ 
ders. After ingestion of the two capsules there was a two hour waiting 
period before beginning the exercise challenge. During this two hour 
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period subjects were allowed to leave the laboratory, but were asked not 
to exercise or eat. After the waiting period the exercise challenge was 
performed in identical fashion to the screening day, with PFTs before 
exercise, after exercise, and after alupent. 
All PFT raw data points were analyzed after being converted to a 
number reflecting the change from that day's baseline PFTs. The change 
from baseline was expressed in two ways: 
1. The absolute change from baseline (simply the difference between 
a PFT at a given time and that PFT prior to drug ingestion on 
that day) and 
2. The percentage change from baseline (calculated by taking the ab¬ 
solute difference, dividing it by the baseline value and multi¬ 
plying by 100). 
In comparing the effects of one drug combination to another absolute 
changes on one day were compared to absolute changes on another day and 
percentage changes from baseline were likewise compared. Thus, the cal¬ 
culations for comparing ascorbic acid to placebo, for example, are actu¬ 
ally differences of differences. All comparisons were made using paired 
Student's t-tests (Snedecor and Cochran, 1967). 
The percentage change from baseline was assumed to more accurately 
reflect changes in the subjects because of the wide range of baseline 
values. Clearly, a drop in MEF40%(P) of 0.3 1/sec is much more signifi¬ 
cant, statistically and clinically, for a subject with a baseline 
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Tables 1 and 2 below give a summary of the anthropometric data obtained 
from the twelve subjects. (Values are the mean +/- one standard devia¬ 
tion. ) 
TABLE 1 























History from questionnaire 
Taking Asthma Medications = 6 
History of Chronic Bronchitis = 0 
History of Smoking = 1 
History of EIB = 12 
worse EIB in cold weather = 9 
worse EIB with URI = 10 
Frequency of Wheezing: 
> once/week = 6 
- once/month = 4 
< once/month = 2 
Wheezing Exacerbated by: 
Animals = 9 
Dusts = 11 
Pollens = 10 
Cigarette smoke = 7 
Cold weather = 10 
Exercise = 12 
History of Allergy : 
Dust, Pollen, Mold = 9 
Hives = 3 
Eczema = 4 
Foods = 4 





8.1 RESPONSE TO EXERCISE WITHOUT DRUGS 
The initial screening day determined whether or not a subject quali¬ 
fied for the remainder of the study and also allowed for the characteri¬ 
zation of the subjects' response to exercise. Tables 3 and 4 give the 
raw data for the response to exercise as measured by the FEV1 and 
MEF40%(P). All parameters showed a significant brochospastic effect at 
five and fifteen minutes post-exercise (P < .05), except for FVC, which 
showed a significant decrease only at the five minute point. Again all 
parameters, except FVC, demonstrated a significant bronchodilatation in 
response to the metaproterenol one hour after exercise (P < .05). These 





FEV1 Screening Day 
Subject Base lmin 5rain 15min 30min 60min post-alupent 
1 3.9 3.9 3.5 3.5 3.5 3.6 3.5 
2 1.9 2.3 1.8 1.8 1.8 2.2 2.7 
3 2.2 1.8 1.6 1.7 1.8 2.0 2.5 
4 3.0 2.6 3.0 3.1 2.8 2.9 3.3 
5 2.9 2.9 2.7 2.8 2.8 3.0 3.4 
6 3.2 3.4 3.3 3.4 3.5 3.5 3.9 
7 2.3 2.2 2.2 2.2 2.2 2.3 2.4 
8 3.5 3.4 3.2 2.9 3.1 3.5 3.8 
9 3.2 2.8 2.7 2.7 2.8 2.9 3.5 
10 3.9 3.8 3.7 3.7 3.9 3.9 4.0 
11 4.1 4.0 4.0 3.9 3.5 4.1 4.0 
12 4.2 4.4 4.2 4.2 4.2 4.1 4.2 
Mean 3.2 3.1 3.0 3.0 3.0 3.2 3.4 




MEF40%(P) Screening Day 
Subject Base lmin 5min 15min 30min 60min post -alupent 
1 2.6 2.5 2.0 2.5 2.8 3.9 3.9 
2 0.9 1.1 0.7 0.8 1.0 1.1 2.0 
3 1.4 0.7 0.4 0.3 0.5 0.4 1.6 
4 1.6 0.9 0.8 1.0 1.3 2.1 3.5 
5 1.5 1.4 1.0 1.0 1.4 1.2 2.1 
6 2.1 1.6 2.0 2.3 2.9 2.9 4.6 
7 0.8 0.6 0.5 0.5 0.7 0.8 1.3 
8 2.1 2.0 1.4 1.2 1.6 2.1 2.9 
9 2.7 0.9 0.8 1.0 1.5 1.8 3.6 
10 2.8 1.9 2.0 2.1 2.3 2.6 3.8 
11 2.9 2.1 2.2 2.5 2.9 3.7 3.6 
12 4.1 4.0 3.2 3.1 3.7 3.3 5.2 
Mean 2.1 1.6 1.4 1.5 1.9 2.2 3.2 
S.D. 1.0 1.0 0.9 0.9 1.0 1.2 1.2 
Of note, these subjects did not demonstrate the typical course of 
EIB entirely. While they did have bronchospasm that was worst at five 
to fifteen minutes post-exercise which improved over the next hour, 
these subjects did not experience bronchodilatation immediately after 
exercise. In fact, both the PEFR and MEF40%(P) were decreased at one 
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minute post-exercise (P < .05), indicating brochospasm already at this 
early point. 
The twelve subjects admitted to the drug portion of the study were 
selected on the basis of having a decrease in MEF40%(P) of at least 20% 
from baseline at some point after exercising. The mean maximal decre¬ 
ment in MEF40%(P) was 39% (+/- 19%), with a range of 22-79%. The mean 
maximal decrease in FEV1 was only 10% (+/- 8%). If a decrease in FEV1 
of at least 10% had been used as the selection criterion, only five of 
the twelve subjects would have been enrolled in the drug trial. 
8.2 RESPONSE TO EXERCISE WITH DRUGS 
Tables 5 and 6 show the baseline PFTs for all subjects before exercise 
on the screening day. This table also expresses the PFTs in terms of 
the predicted values for an individual of the same height, weight, and 
race. 
Tables 7 and 8 then compare the FEV1 and MEF40%(P) baseline values 
(pre-exercise) on all of the study days. This data demonstrates that 
the subjects were starting in essentially the same state each day before 
taking any of the drug combinations (P > .05 for comparing any PFT be¬ 
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Baseline Pulmonary Function Testing 
Vmax50% MEF40% MEF40%(P) 
Subject 1/sec %pred 1/sec 1/sec 
1 5.7 129 4.3 2.6 
2 1.3 31 1.0 0.9 
3 2.0 50 1.4 1.4 
4 3.2 79 2.4 1.6 
5 2.0 38 1.6 1.5 
6 3.3 67 2.4 2.1 
7 1.8 45 1.4 0.8 
8 2.9 57 2.4 2.1 
9 2.7 51 2.2 2.7 
10 4.1 83 3.0 2.8 
11 4.3 83 3.6 2.9 
12 4.9 107 4.1 4.1 
Mean 3.2 69 2.5 2.1 





Comparison of Baseline FEV1 
Subject Screen Placebo Vit C Indocin C + Indo 
1 3.9 3.5 3.8 3.5 3.7 
2 1.9 2.0 2.1 2.1 2.2 
3 2.2 2.0 2.0 2.2 2.0 
4 3.0 2.9 3.1 2.9 3.0 
5 2.9 2.5 2.5 2.6 2.5 
6 3.2 3.6 3.6 3.5 3.6 
7 2.3 2.1 2.0 2.1 2.1 
8 3.5 3.8 3.8 3.9 3.7 
9 3.2 2.9 2.8 3.0 3.4 
10 3.9 3.6 3.8 3.6 3.8 
11 4.1 3.9 4.1 4.1 3.8 
12 4.2 4.1 4.3 4.1 3.9 
Mean 3.2 3.1 3.2 3.1 3.1 













































































































Tables 9 through 16 display the raw data for FEV1 and MEF40%(P) for 
all time points on all five of the study days. (The times given are the 
number of minutes after the completion of the exercise challenge. The 
other values are as follows : "Base " = value prior to drug ingestion, 
"Rest" = value two hours after drug ingestion and prior to the exercise 
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challenge, and "P.A." = post-alupent, value after subjects received me- 
taproterenol upon completing the exercise challenge.) 
The mean values for the group are plotted over time in Figures 3 and 
4. These figures graphically demonstrate the course of EIB in these 
subjects and how there was very little variation produced by any of the 
drugs. There was still significant bronchospasm at five and fifteen 
minutes post-exercise (using both the absolute and percent changes from 
baseline) for almost all parameters as on the screening day (P < .05). 
The only data that varied much from the screening day was the FVC on the 
day that the subjects received ascorbic acid and indomethacin together. 
On that particular day, the FVC was decreased significantly (P < .05) 
from baseline at all time points from one to sixty minutes post-exercise 
(absolute and percent changes). This is markedly different from the 
































FEV1 - Placebo Day 
Subject Base Rest lmin 5min 15min 30min 60min P.A 
1 3.5 3.4 3.7 3.5 3.5 3.5 3.5 3.4 
2 2.0 2.2 2.2 1.8 1.8 2.1 2.1 2.6 
3 2.0 2.1 1.9 1.2 1.1 1.7 2.0 2.5 
4 2.9 3.0 2.8 2.8 2.8 3.0 2.8 3.2 
5 2.5 2.7 2.2 2.3 2.2 2.7 2.5 3.2 
6 3.6 3.4 2.8 2.6 2.5 3.2 3.5 3.9 
7 2.1 2.1 2.0 2.0 2.0 2.2 2.2 2.4 
8 3.8 3.7 4.0 3.6 3.6 3.7 3.7 3.9 
9 2.9 3.0 2.3 2.3 2.3 2.7 3.0 3.6 
10 3.6 3.5 3.3 3.3 3.4 3.5 3.7 4.0 
11 3.9 3.8 4.0 3.8 3.7 3.8 3.9 4.0 
12 4.1 4.1 4.1 4.2 4.0 4.0 4.0 4.0 
Mean 3.1 3.1 2.9 2.8 2.7 3.0 3.1 3.4 





FEV1 - Placebo + Vitamin C Day 
Subject Base Rest lmin 5min 15min 30min 60min P. A 
1 3.8 3.5 3.9 3.8 3.8 3.7 3.6 3.6 
2 2.1 2.0 2.1 1.7 1.7 2.0 2.2 2.6 
3 2.0 2.0 1.5 1.1 1.0 1.3 1.7 2.4 
4 3.1 3.0 3.1 2.9 2.9 3.0 3.1 3.2 
5 2.5 2.9 2.5 2.2 2.6 2.9 2.8 3.3 
6 3.6 3.7 3.6 3.6 3.5 3.6 3.7 3.9 
7 2.0 2.1 2.0 1.9 2.0 2.1 2.1 2.3 
8 3.8 3.9 3.8 3.8 3.9 4.0 4.0 4.2 
9 2.8 3.2 2.5 2.4 2.8 2.6 3.1 3.8 
10 3.8 3.7 3.5 3.5 3.6 3.7 3.7 4.1 
11 4.1 3.9 4.1 3.9 3.9 3.7 3.9 4.0 
12 4.3 4.1 4.3 4.2 4.2 4.2 4.1 4.2 
Mean 3.2 3.2 3.1 2.9 3.0 3.1 3.2 3.5 





FEV1 - Placebo + Indomethacin Day 
Subject Base Rest Imin 5min 15min 30min 60min P.A 
1 3.5 3.4 3.6 3.4 3.4 3.3 3.3 3.4 
2 2.1 2.2 2.6 2.0 2.0 2.1 2.1 2.6 
3 2.2 1.9 1.5 1.1 1.0 1.4 1.7 2.4 
4 2.9 3.0 3.0 3.0 3.0 3.2 3.0 3.3 
5 2.6 3.0 2.7 2.4 2.5 2.7 2.6 3.4 
6 3.5 3.7 3.2 3.1 3.0 3.2 3.4 3.8 
7 2.1 2.1 2.1 2.0 2.1 2.1 2.2 2.3 
8 3.9 3.9 4.1 4.0 3.7 4.1 4.1 4.2 
9 3.0 3.1 2.2 2.2 2.3 2.6 3.1 3.8 
10 3.6 3.8 3.5 3.3 3.6 3.5 3.6 4.0 
11 4.1 3.7 3.9 3.8 4.0 3.8 3.7 4.1 
12 4.1 4.0 4.2 4.2 4.2 4.2 4.2 4.1 
Mean 3.1 3.2 3.0 2.9 2.9 3.0 3.1 3.4 





FEV1 - Vitamin C + Indomethacin Day 
Subject Base Rest lmin 5min 15min 30min 60min P.A. 
1 3.7 3.6 3.6 3.5 3.4 3.4 3.6 3.6 
2 2.2 2.1 2.2 1.7 1.6 1.9 1.9 2.3 
3 2.0 1.9 1.8 1.3 1.2 1.5 1.7 2.5 
4 3.0 3.0 2.8 2.7 2.6 2.8 2.7 3.2 
5 2.5 2.7 2.1 1.7 2.0 2.1 2.4 2.9 
6 3.6 3.5 3.1 2.6 2.3 3.0 3.4 3.8 
7 2.1 2.2 2.1 1.8 2.0 2.0 2.1 2.3 
8 3.7 3.7 4.1 4.0 3.8 3.9 4.0 4.0 
9 3.4 3.4 3.0 3.0 2.8 3.0 3.0 3.7 
10 3.8 3.7 3.4 3.4 3.5 3.6 3.6 4.1 
11 3.8 3.8 3.8 3.7 4.0 3.8 3.8 3.9 
12 3.9 4.0 4.2 4.1 4.0 4.2 4.2 4.4 
Mean 3.1 3.1 3.0 2.8 2.8 2.9 3.0 3.4 





MEF40% (P) - Placebo Day 
Subject Base Rest lmin 5min 15min 30min 60min P. A 
1 4.1 3.4 3.5 3.7 3.3 3.4 3.4 3.9 
2 0.8 1.0 1.1 0.6 0.6 0.8 1.2 2.0 
3 0.9 1.1 0.6 0.2 0.2 0.4 0.9 1.8 
4 1.1 1.6 1.2 0.9 1.2 1.5 1.3 2.4 
5 1.0 1.3 0.7 0.7 0.8 1.4 0.9 1.9 
6 2.6 2.0 0.9 0.6 0.6 1.6 2.4 3.9 
7 0.5 0.5 0.4 0.4 0.3 0.5 0.6 1.0 
8 1.9 2.0 2.5 1.8 1.7 1.9 2.2 2.7 
9 1.6 2.0 0.4 0.4 0.6 1.1 2.0 3.5 
10 2.1 1.9 1.2 1.2 1.7 2.1 2.3 4.5 
11 4.2 4.5 4.1 4.2 3.6 4.2 4.1 4.6 
12 2.7 3.1 2.9 2.9 2.8 3.0 3.0 4.8 
Mean 2.1 2.0 1.6 1.5 1.4 1.8 2.0 3.1 





MEF40%(P) - Placebo + Vitamin C Day 
Subject Base Rest lmin 5min 15min 30min 60min P.A 
1 4.4 3.7 3.7 2.9 3.3 3.5 3.7 5.0 
2 0.8 1.0 0.9 0.3 0.4 0.6 0.9 1.0 
3 0.5 0.2 0.2 0.1 0.0 0.1 0.3 1.4 
4 1.3 1.6 1.6 1.1 1.2 1.5 1.7 2.3 
5 1.1 1.6 1.0 0.7 1.1 1.5 1.2 2.0 
6 2.8 2.9 1.7 1.8 1.8 2.7 2.7 4.0 
7 0.5 0.9 0.4 0.3 0.5 1.0 0.8 1.7 
8 1.9 2.0 2.1 2.0 1.8 2.1 2.2 2.8 
9 1.2 1.9 0.6 0.6 1.0 1.2 1.4 3.1 
10 2.5 2.3 1.5 1.7 2.2 2.3 2.3 4.1 
11 3.3 3.5 3.3 3.2 3.6 3.6 3.6 4.3 
12 2.6 2.4 2.8 2.3 2.6 2.5 2.6 3.7 
Mean 1.9 2.0 1.6 1.4 1.6 1.9 2.0 3.0 




MEF40%(P) - Placebo + Indomethacin Day 
Subject Base Rest lmin 5min 15min 30min 60min P.A 
1 4.2 4.4 3.9 3.1 3.3 3.2 3.7 5.0 
2 1.0 0.9 1.8 0.9 0.8 1.2 0.9 1.3 
3 0.9 0.6 0.3 0.2 0.2 0.3 0.5 1.0 
4 1.6 1.5 1.8 1.5 1.7 2.1 1.9 3.4 
5 0.9 1.4 1.1 0.7 0.8 1.0 0.9 2.2 
6 2.2 2.6 1.3 0.8 1.1 1.5 1.8 3.9 
7 0.4 1.0 0.5 0.3 0.6 0.8 0.7 1.5 
8 2.0 1.9 2.4 1.9 1.8 2.4 2.4 2.9 
9 1.4 1.9 0.2 0.2 0.4 0.7 1.3 2.9 
10 2.6 2.8 2.2 1.7 2.2 1.8 2.7 4.0 
11 4.5 4.5 4.4 4.3 4.2 4.3 4.3 4.6 
12 2.8 3.3 3.5 3.2 3.3 3.3 3.3 3.3 
Mean 2.0 2.2 2.0 1.7 1.8 1.9 2.0 3.0 




MEF40%(P) - Vitamin C + Indomethacin Day 
Subject Base Rest lmin 5min 15min 30min 60min P. A 
1 4.4 3.6 3.3 2.5 2.8 2.8 3.1 4.4 
2 1.0 0.8 0.8 0.4 0.3 0.4 0.7 1.4 
3 0.5 0.6 0.3 0.2 0.2 0.3 0.3 1.4 
4 1.2 1.4 1.0 0.9 0.9 1.2 1.0 2.2 
5 1.0 1.1 0.7 0.3 0.5 0.6 0.9 1.5 
6 1.5 1.4 0.7 0.4 0.3 0.9 1.5 3.1 
7 0.4 0.5 0.4 0.2 0.3 0.6 0.5 1.1 
8 2.1 2.2 3.1 2.6 2.5 2.8 2.7 3.2 
9 1.9 2.3 1.0 1.1 1.2 1.5 1.9 3.0 
10 2.1 2.0 1.3 1.4 1.3 1.5 1.6 2.8 
11 4.3 4.4 4.4 4.5 4.6 4.4 4.4 4.8 
12 2.0 2.3 2.7 2.6 2.6 2.8 2.7 4.0 
Mean 1.9 1.9 1.6 1.4 1.7 2.0 1.8 2.7 




Comparisons between the drug days were made as described in the 
Methods section. There were no significant differences between the ef¬ 
fects of ascorbic acid and placebo on the response to exercise (P > .05) 
at any of the time points. Likewise, there were no significant differ¬ 
ences between the effects of indomethacin and placebo. However, the 
combination of ascorbic acid and indomethacin did produce some small, 
yet statistically significant, differences from placebo. This drug com¬ 
bination produced a decrement in the FVC that was 0.2 1/sec (or approxi¬ 
mately 5%) lower than the placebo values at 30 and 60 minutes post-exer¬ 
cise and after the metaproterenol. Despite this, comparing the ascorbic 
acid and indomethacin combination to ascorbic acid alone did not demon¬ 
strate any statistically significant differences. 
In addition to looking at the effects of the drugs on EIB, this 
study was also able to assess their effects on resting airway tone. 
This was accomplished by comparing the pre-drug baseline ("Base" in the 
tables) with the post-drug, resting PFT's done before the exercise chal¬ 
lenge ("Rest" in the tables). None of the drug combinations had a sig¬ 
nificant effect on resting lung function (all P values > .05). 
Figure 5 illustrates the FEV1 curves for three subjects in the group 
•who had less EIB on the days when ascorbic acid was given. In these 
three subjects the suggested "protective action" of ascorbic acid ap¬ 
peared to be blocked by the addition of indomethacin. Three other sub¬ 
jects appeared to have worse EIB after treatment with ascorbic acid, 
while six subjects appeared to have EIB of the same severity with ascor¬ 
bic acid. Indomethacin alone did not have a significant effect on any 
of the subjects, regardless of their response to ascorbic acid. The 
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three subjects who responded favorably to ascorbic acid did not differ 
from the other subjects in terms of any of the following parameters: 
age, sex, history of allergies, asthma, or EIB, or severity or pattern 
of EIB response to screening exercise challenge. However, these three 
subjects did have more severe asthma as measured by their baseline FEV1 
as percent of predicted. The ascorbic acid responders had an FEV1 that 
was, on average, 75% of predicted. The other nine subjects had an aver¬ 
age FEV1 that was 96% of predicted. Similarly, the three ascorbic acid 
responders had lower percent predicted values than the other subjects 
for FVC, PEFR, and Vmax50%. The three subjects who appeared to have 
worse EIB after ascorbic acid treatment could not be distinguished from 
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9.1 RESPONSE TO EXERCISE WITHOUT DRUGS 
Data from the initial screening day of the study documented EIB in all 
twelve subjects on the basis of at least a 20% drop in MEF40%(P) from 
baseline at some point after exercise. These subjects may be separated 
into two groups based on the criterion of Schachter et al (Schachter, 
1978a). It was in that study that the researchers were able to separate 
subjects with EIB into two groups: 
1. One group with decreased air flow using measures of small airway 
status (MEF40% and MEF40%(P)) and 
2. A second group with decreased flow according to both small and 
large (FEV1) airway parameters. 
In the present study six subjects had post-exercise decreases in FEV1 of 
at least 10% on the screening challenge, while the other six subjects 
did not decrease their FEV1 by that much. This study, therefore, con¬ 
firms the observation that two distinct patterns of airway obstruction 
in EIB can be described. 
One somewhat unexpected finding in the screening data was that the 
subjects as a group showed significant bronchospasm as early as one min¬ 
ute after exercise, with MEF40%(P) decreasing from 2.1 +/- 1.0 1/sec at 
baseline to 1.6 +/- 1.0 1/sec at one minute. EIB has been described 




preceded by bronchodilatation immediately post-exercise (McFadden, 
1983). However, one must recall that each time point in this study is 
actually the mean of three PEFV and MEFV curve maneuvers done one minute 
apart. Thus, the value for the one minute post-exercise point is really 
the mean of three values obtained at one, two, and three minutes post¬ 
exercise. Suspecting that taking the mean of these three measurements 
might have obscured the initial bronchodilatation because of subsequent, 
progressive bronchoconstriction in the later values, the MEF40%(P) was 
re-examined. This was done using the data from the screening day, look¬ 
ing at the individual curves that made up each time point. Indeed, the 
three curves did demonstrate a progressive decline in MEF40%(P), with 
the individual values being: 
1. One minute post-exercise = 1.8 +/- 1.0 1/sec, 
2. Two minutes post-exercise = 1.6 +/- 1.1 1/sec, and 
3. Three minutes post-exercise = 1.4 +/- 0.9 1/sec. 
Even the first value, however respresents a 0.3 1/sec decrease from 
baseline, but this did not achieve statistical significance (P > .10). 
It may be that the post-exercise bronchodilatation is quite short-lived 
and was not picked up in this study because the first value was not ob¬ 
tained until a full minute after exercise had ceased. Two studies using 
exercise challenges and PFTs the most similar to this study also did not 
demonstrate significant bronchodilatation immediately post-exercise 
(Schachter, 1978a and Schachter, 1982). In fact, in the latter of these 
studies, the only value reaching statistical significance immediately 
after exercise was a decrease in FVC. 
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All PFTs demonstrated a bronchodilating response to metaproterenol 
(except FVC) as expected. 
9.2 RESPONSE TO EXERCISE WITH DRUGS 
This study was designed to confirm the protective effect of ascorbic 
acid in EIB and to examine the mechanism of such an effect. Our working 
hypothesis was that this effect was due to an alteration in prostaglan¬ 
din metabolism. It was expected that this protection would be blocked 
by the simultaneous administration of indomethacin, as had been shown to 
be the case with methacholine induced bronchospasm (Ogilvy, 1981 and 
Mohsenin, 1983). However, the present study failed to confirm the exis¬ 
tence of a protective effect of ascorbic acid against EIB. There were 
some trends in the data suggesting a possible benefit at fifteen minutes 
post-exercise, with the FEV1 5% and MEF40%(P) 9% better, respectively, 
with ascorbic acid than with placebo. Neither of these values, however, 
achieved statistical significance (P = .14 and P = .11, respectively). 
The FVC was only 0.5% better for ascorbic acid than placebo at the same 
time point. These findings are in contrast to Schachter and Schlesinger 
(Schachter, 1982) who found the protective effect trend in all parame¬ 
ters and at all times measured (immediate post-exercise, five minutes 
post-exercise, and after metaproterenol). The values that achieved sig¬ 
nificance in their study were those reflecting a protective effect on 
the bronchoconstriction of larger airways (FEV1 and FVC). Our work does 
not support these earlier results. 
It should be noted that when individual subjects were examined in 
this earlier study only eight out of the twelve subjects showed less EIB 
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when ascorbic acid was administered. Of these eight subjects, five in¬ 
dividuals had more significant benefit from the ascorbic acid (greater 
than a 10% improvement in FEV1 at five minutes post-exercise when com¬ 
pared to the response to placebo). These five subjects, like the ascor¬ 
bic acid responders in our study, had a lower percent predicted of FEV1 
than the other subjects in the study (63% and 83% of predicted, respec¬ 
tively). Thus, it may be that those subjects with a lower percent pre¬ 
dicted of FEV1 are more likely to derive benefit from treatment with as¬ 
corbic acid. Furthermore, a possible explanation for the differences 
between our results and those of the earlier study may be the greater 
number of "ascorbic acid responders" in Schachter and Schlesinger1s 
group. 
The five subjects in Schachter and Schlesinger1s study who had the 
greatest response to ascorbic acid were also distinguishable from the 
other subjects by their more severe EIB on the screening exercise chal¬ 
lenge. This characteristic was apparent in the PFTs that reflect both 
large and small airway status. The ascorbic acid responders had mean 
FEV1 and MEF40%(P) of 78% and 42% of their baseline values, respective¬ 
ly, at five minutes post-exercise. The remaining subjects had mean FEV1 
and MEF40%(P) of 89% and 62%, respectively, at the same time point. 
This difference between ascorbic acid responders and non-responders was 
not evident in the present study. In our study the responders had five 
minute FEV1 and MEF40%(P) values of 93% and 64%, while the non-respond¬ 
ers had values that were 93% and 65% of baseline. Thus, both studies 
suggest that ascorbic acid responders may be those individuals with a 
lower baseline FEV1 (as percent of predicted value). However, this 
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study does not confirm the finding in the earlier investigation that as¬ 
corbic acid responders are also those who experience greater bronchos- 
pasm in response to exercise. 
There are really very few differences between this protocol and the 
one used by Schachter and Schlesinger. This study looked at additional 
drug combinations and carried the measurement of PFTs out for a longer 
period of time after exercise ended. The exercise challenges and PFTs 
themselves were carried out in virtually the same fashion in the two 
studies. This study had subjects wait two hours between drug ingestion 
and exercise challenge, while the earlier study utilized only a 90 min¬ 
ute waiting period. This is probably not a significant difference, 
since our study gave subjects 750 mg of ascorbic acid, while Schachter 
and Schlesinger1s subjects ingested only 500 mg. 
The next thing to examine for differences between these two studies 
is the subjects themselves. Already mentioned above was the apparent 
difference in the number of "ascorbic acid responders" between the two 
studies and the difference in the severity of EIB between the "respond¬ 
ers" in these investigations. The difference in number of "responders" 
may also be reflected in this study group appearing to have a slightly 
healthier baseline than the previous study group, with FVC, FEV1, and 
PEFR close to predicted values (102%, 90%, and 94%, respectively), as 
opposed to the earlier group where these parameters were 87%, 75%, and 
78% of predicted. The baseline MEF40%(P) for the two cohorts was almost 
identical: 2.1 +/- 1.0 and 2.1 +/- 1.1 1/sec. Many of the other meas¬ 
urements are also quite similar. There are no strong factors distin¬ 
guishing these two study populations. 
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Another possible explanation for the different results in the stud¬ 
ies lies in a phenomenon alluded to earlier: two different patterns of 
airway obstruction in EIB, possibly defining two distinct subgroups of 
asthmatics. The study by Schachter et al describing these two patterns 
of airway response to exercise (Schachter, 1978a) is not the only work 
that has revealed such a dichotomy in EIB. Studies looking at the ef¬ 
fects of various pharmacological agents on EIB have demonstrated that 
some subjects have the predominant site of obstruction in their periph¬ 
eral airways. This group of subjects had EIB attenuated by DSCG, but 
did not derive any benefit from anticholinergic agents (McFadden, 1977b 
and Thomson, 1978). Conversely, a small group of subjects are protected 
from EIB by atropine and not by DSCG (Godfrey, 1976). There is yet a 
third subpopulation whose main site of obstruction is in the larger air- 
ways, yet they have less EIB when given either DSCG or ipratropium brom¬ 
ide (another anticholinergic agent) (McFadden, 1977b and Thomson, 1978). 
Further evidence for dual mechanisms in EIB is provided by a study where 
ipratropium provided protection against bronchospasm induced by isocap- 
nic hyperventilation in subjects who normally experienced bronchospasm 
after many such challenges repeated over a short interval without this 
drug. Subjects who did not continue to have bronchospasm after repeated 
challenges (analogous to the refractory period in EIB) did not benefit 
from ipratropium (Wilson, 1982). The hypothesis that emerges from this 
work is one where EIB actually may develop by two different mechanisms 
in different subjects: 
1. A peripheral airway response that is from mediator release and 
responds to DSCG and 
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2. A central airway response that is mediated by reflexes and re¬ 
sponds to anticholinergic medications. 
The existence of such heterogeneity may help explain why studies have 
produced conflicting results when they have examined only one mechanism 
or the other at any single time. 
In the present study we were unable to demonstrate a therapeutic ef¬ 
fect of ascorbic acid for the group of subjects as a whole. While not 
statistically significant, there was a subgroup of three subjects who 
did appear to have their EIB attenuated by ascorbic acid, as shown in 
Figure 5. In this group the response to indomethacin was consistent 
with our hypothesis. This raises the possibility that the response to 
ascorbic acid may be another factor that can distinguish different types 
of asthmatics, possibly related to the different proposed mechanisms for 
EIB. In this small group of responders to ascorbic acid, however, there 
were no clear trends in small or large airway patterns identified that 
would suggest where ascorbic acid might be having its effect. Schachter 
and Schlesinger's data supports an effect of ascorbic acid on large air¬ 
ways because FEV1 and FVC were the parameters that indicated a protec¬ 
tive effect on a statistically significant level (Schachter, 1982). 
This would be consistent with a role for ascorbic acid in the vagally 
mediated type of larger airway bronchospasm, and is further supported by 
work on the effect of ascorbic acid on methacholine induced bronchospasm 
and Mohsenin, 1983). Since the protection of ascorbic acid against me¬ 
thacholine is blocked by indomethacin, one would have to postulate an 
even more complex interaction between ascorbic acid, prostaglandins, and 
the cholinergic nervous system. (Of course, this might be even more 
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complicated given the trends in our study showing some effect of ascor¬ 
bic acid on smaller airway parameters as well.) 
Our results demonstrating no effect of either ascorbic acid or in- 
domethacin on baseline airway tone agree with the earlier studies (Ogil- 
vy, 1981, Schachter, 1982, and Mohsenin, 1983). This supports the no¬ 
tion that if ascorbic acid has a therapeutic effect, it probably works 
on a dynamic process in EIB, such as prostaglandin generation. 
What is clear from the above discussion is the need for studies uti¬ 
lizing a larger number of subjects to look at ascorbic acid and EIB and 
the identification of a subgroup of asthmatics that are responsive to 
ascorbic acid. The magnitude of the effect of ascorbic acid in such a 
subgroup remains to be determined, but the experience in our study and 
the previous study of Schachter and Schlesinger suggest that it is not 
very great. 
Another promising direction in this research is the development of 
the inhibitors of the various steps in arachidonic acid metabolism (Van 
Wauwe, 1983 and Weichman, 1984). Once such agents are adapted for use 
in animal studies and then human clinical trials, one will be better 
able to tease apart the relative contributions of leukotrienes and pros¬ 
taglandins to EIB and how ascorbic acid may influence these pathways. 
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